<scp>FLIP</scp> as a therapeutic target in cancer
Luke Humphreys(Queen's University Belfast), Daniel B. Longley(Queen's University Belfast), Margarita Espona‐Fiedler(Umeå University)
Cited by 86
Related Papers
MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma
|Modern Pathology|2014|174
Synthetic Prodiginine Obatoclax (GX15‐070) and Related Analogues: Anion Binding, Transmembrane Transport, and Cytotoxicity Properties
|Chemistry - A European Journal|2011|116
Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. obatoclax
|Biochemical Pharmacology|2011|74
Down-Regulation of miR-29b Is Essential for Pathogenesis of Uterine Leiomyoma
|Endocrinology|2014|73
Overcoming therapy resistance in pancreatic cancer: New insights and future directions
|Biochemical Pharmacology|2024|57